Refractory (planetary science)

Cytokine release syndrome

Chemotherapy

Astrobiology

Immunotherapy

Fludarabine

Gastroenterology

Adverse effect

Biology

Cancer

Cyclophosphamide

Internal medicine

Leukemia

Minimal residual disease

Surgery

Immunology

Chimeric antigen receptor

Medicine

Blood

KTE-X19 at 1 × 10 6 CAR T cells per kg had high manufacturing success and manageable safety that further improved with revised AE management. KTE-X19 resulted in high complete remission rates and undetectable residual disease; median response duration (1 × 10 6 dose) was 18 months.

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results